SLC22A17 and B-cell chronic lymphocytic leukemia: Surface expression of NGAL-R by CLL cells from patients in remission (regardless of the therapeutic regimen) was significantly lower than in the untreated CLL group (p = 0.040) (Figure 3C), and was similar to those in normal PBMCs (p = 0.975).